Coherus Oncology (CHRS) EPS (Diluted) Growth (3y) (2018 - 2026)
Coherus Oncology (CHRS) EPS (Diluted) Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 61.64% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 36.83% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.90% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.81% |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | 35.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.41% |
| Mar 31, 2026 | 77.98% |
| Dec 31, 2025 | 28.02% |
| Sep 30, 2025 | 27.43% |
| Jun 30, 2025 | 87.24% |
| Mar 31, 2025 | 60.07% |
| Dec 31, 2024 | 59.55% |
| Sep 30, 2024 | 38.49% |
| Jun 30, 2024 | 42.98% |
| Mar 31, 2024 | 37.04% |
| Dec 31, 2023 | -110.11% |
| Sep 30, 2023 | -47.65% |
| Jun 30, 2023 | -39.20% |
| Mar 31, 2023 | -58.72% |
| Dec 31, 2022 | -50.56% |
| Sep 30, 2022 | -55.61% |
| Jun 30, 2022 | -58.77% |
| Mar 31, 2022 | -62.60% |
| Dec 31, 2021 | 14.32% |
| Sep 30, 2021 | 17.46% |